OCTH.F logo

Oxford Cannabinoid Technologies Holdings OTCPK:OCTH.F Stock Report

Last Price

US$0.0028

Market Cap

US$3.0m

7D

0%

1Y

n/a

Updated

05 Aug, 2024

Data

Company Financials

Oxford Cannabinoid Technologies Holdings Plc

OTCPK:OCTH.F Stock Report

Market Cap: US$3.0m

OCTH.F Stock Overview

A pharmaceutical company, engages in the research, development, and commercialization of cannabinoid-based prescription medicines. More details

OCTH.F fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health4/6
Dividends0/6

My Notes

Capture your thoughts, links and company narrative

Oxford Cannabinoid Technologies Holdings Plc Competitors

Price History & Performance

Summary of share price highs, lows and changes for Oxford Cannabinoid Technologies Holdings
Historical stock prices
Current Share PriceUS$0.0028
52 Week HighUS$0.044
52 Week LowUS$0.0028
Beta4.18
1 Month Change0%
3 Month Change-93.68%
1 Year Changen/a
3 Year Changen/a
5 Year Changen/a
Change since IPO-94.40%

Recent News & Updates

Recent updates

Shareholder Returns

OCTH.FUS PharmaceuticalsUS Market
7D0%1.6%-2.2%
1Yn/a9.7%23.9%

Return vs Industry: Insufficient data to determine how OCTH.F performed against the US Pharmaceuticals industry.

Return vs Market: Insufficient data to determine how OCTH.F performed against the US Market.

Price Volatility

Is OCTH.F's price volatile compared to industry and market?
OCTH.F volatility
OCTH.F Average Weekly Movementn/a
Pharmaceuticals Industry Average Movement10.4%
Market Average Movement6.3%
10% most volatile stocks in US Market17.0%
10% least volatile stocks in US Market3.1%

Stable Share Price: OCTH.F's share price has been volatile over the past 3 months.

Volatility Over Time: Insufficient data to determine OCTH.F's volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
20177Clarissa Sowemimo-Cokerwww.oxcantech.com

Oxford Cannabinoid Technologies Holdings Plc, a pharmaceutical company, engages in the research, development, and commercialization of cannabinoid-based prescription medicines. Its lead drug candidate consists of OCT461201, an CB2 receptor, that is in phase – I clinical trial for use in the treatment of chemotherapy-induced peripheral neuropathy and irritable bowel syndrome (IBS), as well as in neuropathic and visceral pain conditions. The company is also developing OCT130401, which is in pre-clinical development for the treatment of trigeminal neuralgia.

Oxford Cannabinoid Technologies Holdings Plc Fundamentals Summary

How do Oxford Cannabinoid Technologies Holdings's earnings and revenue compare to its market cap?
OCTH.F fundamental statistics
Market capUS$3.05m
Earnings (TTM)-US$5.43m
Revenue (TTM)n/a

0.0x

P/S Ratio

-0.6x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
OCTH.F income statement (TTM)
RevenueUK£0
Cost of RevenueUK£2.33m
Gross Profit-UK£2.33m
Other ExpensesUK£1.91m
Earnings-UK£4.24m

Last Reported Earnings

Oct 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-0.0039
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0%

How did OCTH.F perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/08/05 20:20
End of Day Share Price 2024/05/08 00:00
Earnings2023/10/31
Annual Earnings2023/04/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Oxford Cannabinoid Technologies Holdings Plc is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Soo RomanoffEdison Investment Research